Latest Pharmacogenetics Stories
CINCINNATI, Feb. 1, 2011 /PRNewswire/ -- AssureRx Health, Inc. today announced the appointments of two senior executives in key roles to drive company growth. Donald R. Wright, Jr. has been appointed as executive vice president & chief operating officer and John A.
AUSTIN, Texas, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that it has commercially launched its first pharmacogenetic test, the xTAGÂ® CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme.
MORRISVILLE, N.C., Nov.
VISTA, Calif., Oct. 26 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITIÂ® CYP2C19 Assay.
RICHMOND, Va. and CINCINNATI, Sept. 28 /PRNewswire/ -- Diamond Healthcare Corporation and AssureRx Health, Inc.
WASHINGTON and LONDON, September 15, 2010 /PRNewswire/ -- Diaceutics Limited (http://www.diaceutics.com) and London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, today announce a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups.
CINCINNATI, Aug. 10 /PRNewswire/ -- AssureRx Health, Inc.
LONDON, July 22, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that it has augmented the strength of its team with the appointment of two senior advisers, Professors Stephen DeCherney and Munir Pirmohamed.
LOUISVILLE, Ky., June 24/PRNewswire/ -- PGXL, a Louisville-based molecular diagnostics laboratory, announced a new contractual agreement with Generation Health, Inc. (GH). The agreement makes PGXL a preferred genetic testing lab for GH.
- A political dynamiter.